Biogen | BIIB - Ordinary Share Capital


Biogen reported $146.7M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Acadia Pharmaceuticals USD 168.71M 104K Sep/2025
ALKERMES USD 165.1M 49K Sep/2025
Amgen USD 539M 1000K Dec/2025
Bayer EUR 982.42M 0 Sep/2025
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 192.1M 97K Sep/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Esperion Therapeutics USD 112K 11K Sep/2023
Gilead Sciences USD 1.24B 1000K Dec/2025
Incyte USD 198.46M 2.33M Dec/2025
Merck USD 2.49B 15.79M Sep/2025
Moderna USD 391M 2M Sep/2025
Neurocrine Biosciences USD 100.1M 400K Dec/2025
Novartis USD 1.94B 23.4M Jun/2025
Pfizer USD 5.69B 1000K Sep/2025
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Puma Biotechnology USD 5K 0 Jun/2024
Regeneron Pharmaceuticals USD 105.3M 1.1M Sep/2025
Sarepta Therapeutics USD 104.77M 7.06M Sep/2025
Teva Pharmaceutical Industries USD 1.15B 0 Dec/2025
Ultragenyx Pharmaceutical USD 96.44M 88K Sep/2025
United Therapeutics USD 42.9M 42.1M Sep/2025
Vertex Pharmaceuticals USD 254M 0 Dec/2025